C-reactive protein in the emergency department: Has it found a clinical application?;Proteína C reactiva en el servicio de urgencias: ¿Ha encontrado una aplicación clínica?

Revista Espanola de Cardiologia

Volumn 60, Issue 8, 2007, Pages 797-800

  Kaski, Juan C ^a,b   Fernández Bergés, Daniel ^c  

^a Centro de Investigación en Biología Cardiovascular

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Hospital de Don Benito   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; TROPONIN;

ATHEROMATOSIS; CARDIOLOGIST; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; EDITORIAL; ELECTROCARDIOGRAPHY; HEART DISEASE; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PROGNOSIS; THORAX PAIN; THROMBOSIS; ACUTE DISEASE; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; EMERGENCY HEALTH SERVICE; NOTE; SYNDROME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; EMERGENCY SERVICE, HOSPITAL; HUMANS; MYOCARDIAL INFARCTION; SYNDROME;

EID: 34548009646     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13108992     Document Type: Editorial

References (16)

1. García-Moll X. Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting? Rev Esp Cardiol. 2005;58:615-7.
2. Naghavi M, Libby P, Falk E, Casscells SW , Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664-72.
3. Danesh J, Wheeller JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
4. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al Comparative impact of multiple biomarkers and N-terminal-pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Herat Outcomes Prevention Evaluation (HOPE) study. Circulation. 2006;114:201-8.
5. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronay syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998;31:1460-5.
6. Jaffe AS, Vatus H. Acute coronary syndrome biomarkers. The need for more adequate reporting. Circulation. 2004;110:104-6.
7. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
8. Pearson TA, Mensah GA, Wayne Alexander R, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
9. Lozano T, Ena J, Almenar V, Graells M, Molina J, Antorrena I, et al. Evaluación de los pacientes con dolor torácico agudo de origen incierto mediante la determinación seriada de los niveles de proteína C reactiva de alta sensibilidad. Rev Esp Cardiol. 2007; 60:817-24.
10. Newby LK, Storrow AB, Gibler WB , Garvey JL, Tucker JF, Kaplan AL, et al. Bedside multimarker testing of risk stratification in chest pain units. The chest pain evaluation by creatine kinase-MB, myoglobin and troponin I (CHECKMATE) study. Circulation. 2001;103;1832-7.
11. Pastor Torres LF, Pavón-Jiménez R, Reina Sánchez M, Caparros Valderrama J, Mora Pardo JA. Unidad de dolor torácico: seguimiento a un año. Rev Esp Cardiol. 2002;55:1021-7.
12. Sanchis J, Boda V, Yacer A, Núñez J, Ferrero JA, Chorro FJ. Valor de la prueba de esfuerzo precoz en un protocolo de unidad de dolor torácico. Rev Esp Cardiol. 2002;55:1089-92.
13. Bragulat E, López B, Miró O, Coll-Vinent B, Jiménez S, Aparicio MJ, et al. Análisis de la actividad de una unidad estructural de dolor torácico en un servicio de urgencias hospitalario. Rev Esp Cardiol. 2007;60:276-84.
14. Sánchez PL, Rodríguez MV, Villacorta E, Albarrán C, Cruz I, Moreiras JM, et al. Kinetics of C-reactive proteine release in different forms of acute coronary syndrome. Rev Esp Cardiol. 2006;59:441-7.
15. Domínguez-Rodríguez A, García-González M, Abreu-González P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to Creactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2006;26:89-93.
16. Rudnika AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and Von Willebrand factor in a 45-year-old population. Circulation. 2007;115:996-1003.